JAK2 V617F Allele Burden Kit, tap a thumbnail to see more views.
JAK2 V617F Allele Burden Kit
The TRUPCR® JAK2 V617F Allele Burden Kit is a Real-time polymerase chain reaction (PCR) assay for the quantification of V617F mutation in JAK-2 (Janus Kinase 2) gene against a background of wild-type genomic DNA. This mutation is a guanine to thymidine transversion in position 1849 of the JAK-2 gene, which leads to a valine to phenylalanine substitution in position 617 of the protein (V617F). The test utilizes mutation-specific primers and a JAK-2 V617F/G1849T targeted fluorescent probe to detect low-copy number (1%) JAK-2 V617F-mutant DNA in cancer tissue. The TRUPCR JAK-2 V617F Mutation Detection Kit is a highly selective and sensitive assay for quantification of V617F mutation in the JAK-2 oncogene.
Quote-based, no public pricing. Add to your quote and our specialists put together a proposal with the right documentation, typically within 24 hours.
This kit in detail
The TRUPCR® JAK2 V617F Allele Burden Kit is a Real-time polymerase chain reaction (PCR) assay for the quantification of V617F mutation in JAK-2 (Janus Kinase 2) gene against a background of wild-type genomic DNA. This mutation is a guanine to thymidine transversion in position 1849 of the JAK-2 gene, which leads to a valine to phenylalanine substitution in position 617 of the protein (V617F). The test utilizes mutation-specific primers and a JAK-2 V617F/G1849T targeted fluorescent probe to detect low-copy number (1%) JAK-2 V617F-mutant DNA in cancer tissue.
The TRUPCR JAK-2 V617F Mutation Detection Kit is a highly selective and sensitive assay for quantification of V617F mutation in the JAK-2 oncogene.
- Quantifies JAK2 V617F allele burden with 1% sensitivity
- Calibrated to WHO reference standards for global clinical consistency
- High specificity using mutation-targeted hydrolysis probes
- Ready-to-use format, compatible with major real-time PCR systems
Quantitative PCR Detection of JAK2 V617F Allele Burden in Myeloproliferative Neoplasms
The TRUPCR® JAK2 V617F Allele Burden Kit is a CE-IVD certified, real-time PCR assay developed for the quantification of the V617F mutation in the JAK2 gene from genomic DNA. Designed to measure the mutant allele burden in patients with myeloproliferative neoplasms (MPNs), this assay enables precise quantification of JAK2 V617F copies against a wild-type DNA background. The kit utilizes mutation-specific primers and a JAK2 V617F-targeted hydrolysis probe, achieving a detection limit as low as 1% mutant DNA. It is calibrated against the WHO 1st International Reference Panel and is compatible with standard real-time PCR platforms.
Molecular Background
JAK2 (Janus Kinase 2) is a non-receptor tyrosine kinase that plays a central role in cytokine signaling and hematopoietic cell regulation. It activates intracellular pathways via phosphorylation of downstream targets like STAT5, promoting cell proliferation, differentiation, and survival.
A single nucleotide mutation in JAK2-c.G1849T; p.Val617Phe (V617F)-is one of the most common somatic mutations associated with BCR-ABL1-negative MPNs. This gain-of-function mutation results in constitutive activation of JAK-STAT signaling, driving clonal expansion of hematopoietic cells.
The JAK2 V617F mutation is found in:
- 95–98% of polycythemia vera (PV) cases
- 50–60% of essential thrombocythemia (ET) and primary myelofibrosis (PMF)
- Occasionally in other myeloid neoplasms, such as chronic myelomonocytic leukemia and myelodysplastic syndrome
Detection of this mutation is included in the WHO diagnostic criteria for MPNs and is essential for diagnosis, risk stratification, and treatment monitoring. JAK2 allele burden may also decrease with successful therapy and reappear during relapse, making it a valuable tool for disease tracking.
Assay Performance & Utility
The TRUPCR® JAK2 V617F Allele Burden Kit delivers accurate, reproducible quantification of JAK2 mutant DNA in a background of wild-type DNA. The assay is optimized to:
- Detect as low as 1% mutant allele
- Quantify allele burden for treatment monitoring and risk assessment
- Provide high specificity using site-directed hydrolysis probes
- Align with WHO standards for clinical consistency
This assay is ideal for use in clinical molecular laboratories, hematology/oncology centers, and monitoring post-transplant or therapy response in MPN patients.
Technical Specifications
- Assay Type: Real-time PCR (quantitative)
- Target Mutation: JAK2 V617F (c.G1849T; p.Val617Phe)
- Sample Type: Genomic DNA from whole blood
- Input Requirement: 50–200 ng per reaction
- Sensitivity: Detects 1% mutant allele fraction
- Probe Chemistry: Mutation-specific hydrolysis probes
- Compatible Instruments: ABI 7500, Roche LightCycler®, Bio-Rad CFX96™, and others
- Multiplex Master Mix
- JAK2 Mutant Primer Probe Mix
- JAK2 WT Primer Probe Mix
- JAK2 Mutant Standards
- JAK2 WT Standards
- Negative Control
Datasheets and regulatory documentation
Everything your quality team needs for evaluation and procurement.
Product Catalogus
Frequently paired with this kit
Other assays and instruments lab teams add alongside the JAK2 V617F Allele Burden Kit.
Add this kit to your quote
Tell us the platforms and throughput you’re planning for and our specialists will put together a clear proposal with the right documentation, no public pricing, just a considered answer.
